CSL Limited
CSL
Rangering i aksjer
#363
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aksjekurs
$138.58
Markedsverdi
$66.50B
Endring (1 dag)
0.72%
Endring (1 år)
-2.29%
Land
AU
Handel CSL Limited (CSL)
Kategori
Healthcare
Inntekter for CSL Limited (CSL)
Inntekter i Jun 2026 TTM: $-4.02B
Ifølge CSL Limited sine nyeste økonomiske rapporter er selskapets nåværende resultat $-4.02B. I 2024 hadde selskapet et resultat på $3.38B, en økning sammenlignet med resultatet i 2023, som var $2.66B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for CSL Limited fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-4.02B | -207.85% |
| 2025 | $3.72B | 10.34% |
| 2024 | $3.38B | 26.74% |
| 2023 | $2.66B | -4.19% |
| 2022 | $2.78B | -6.80% |
| 2021 | $2.98B | 15.92% |
| 2020 | $2.57B | 9.89% |
| 2019 | $2.34B | 2.63% |
| 2018 | $2.28B | 35.00% |
| 2017 | $1.69B | 8.61% |
| 2016 | $1.56B | -9.22% |
| 2015 | $1.71B | 6.84% |
| 2014 | $1.60B | 19.64% |
| 2013 | $1.34B | 5.36% |
| 2012 | $1.27B | -7.31% |
| 2011 | $1.37B | 38.29% |
| 2010 | $992.87M | 11.00% |
| 2009 | $894.45M | 2.37% |
| 2008 | $873.74M | 56.73% |
| 2007 | $557.47M | 493.43% |
| 2006 | $93.94M | -74.77% |
| 2005 | $372.39M | 201.20% |
| 2004 | $123.64M | 168.99% |
| 2003 | $45.96M | -7.38% |
| 2002 | $49.63M | -8.38% |
| 2001 | $54.17M | 88.04% |
| 2000 | $28.81M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -231.34% |
US
|
|
| $-3.09B | -23.14% |
US
|
|
| - | - |
CH
|
|
| $1.95B | -148.57% |
NL
|
|
| $3.01B | -174.84% |
BE
|
